On behalf of the entire Tilray team, I am pleased to announce that Tilray has formed a strategic alliance with a major pharmaceutical company. Tilray is now allied with Sandoz Canada Inc., a part of the Novartis group and a global leader in generic pharmaceuticals.
This alliance is a major milestone on the long road to legitimizing medical cannabis as conventional medicine. To our knowledge, Tilray is the first federally-licensed producer of medical cannabis in Canada to form a strategic alliance with a global pharmaceutical company to improve the availability and quality of medical cannabis products for patients in need.
Pending necessary regulatory approvals and the execution of a definitive agreement between the two companies:
- Tilray will leverage Sandoz Canada’s best-in-class knowledge to educate Canadian pharmacists and physicians about Tilray medical cannabis products;
- Tilray will become the exclusive partner of Sandoz with respect to non-smokable/ non-combustible medical cannabis products;
- Tilray will partner with Sandoz to develop new and innovative medical cannabis products that offer an alternative to smokable/ combustible products;
- And subject to future regulatory changes, Sandoz Canada, known for its supply reliability, will wholesale and distribute non-smokable/ non-combustible Tilray products to Canadian hospitals and pharmacies.
This strategic alliance builds on Tilray’s pioneering track-record as a company committed to making high-quality medical cannabis products available to patients in need around the globe. In addition to the agreement with Sandoz Canada, Tilray has formed relationships with NOWEDA, one of Germany’s largest pharmaceutical distributors that distributes medicines to more than 20,000 pharmacies across Germany, and Shoppers Drug Mart, Canada’s largest pharmacy chain.
This news is part of a series of major announcements Tilray will be making in the coming weeks. I look forward to sharing even more positive news with you soon.
Brendan Kennedy, Tilray CEO